# XWPharma

> XWPharma is a clinical-stage neuroscience biotech developing internally discovered small-molecule medicines for sleep, depression and other central nervous system disorders. Its lead sleep candidate, valiloxybate, was licensed in 2025 for global development and commercialization outside mainland China, Hong Kong and Macau.

- **Founded:** 2014
- **Headquarters:** Redwood City, United States
- **Founders:** Jia-Ning Xiang (Founder and Chief Scientific Officer; former CEO)
- **Products:** Valiloxybate (XW10172), XW10508
- **Notable:** 2019 US FDA orphan-drug designation for the company’s narcolepsy candidate then called XWL-008., 2021 Phase 1 pharmacokinetic results for XW10172 presented at SLEEP 2021., 2025 exclusive valiloxybate license with $20 million in upfront payments.

## Products & services

- **Valiloxybate (XW10172)** — Investigational once-at-bedtime, salt-free oxybate candidate for sleep disorders including narcolepsy and idiopathic hypersomnia; licensed to Avadel in 2025, with China-region exclusions.
- **XW10508** — Investigational oral, once-daily glutamatergic NMDA antagonist and AMPA activator studied for treatment-resistant depression and chronic pain.

## Achievements

- 2019 US FDA orphan-drug designation for the company’s narcolepsy candidate then called XWL-008.
- 2021 Phase 1 pharmacokinetic results for XW10172 presented at SLEEP 2021.
- 2025 exclusive valiloxybate license with $20 million in upfront payments.

## Latest updates

- **2026-02** — Alkermes said it had closed its acquisition of Avadel and planned to continue advancing valiloxybate in early clinical development.
- **2025-09** — XWPharma and Avadel announced an exclusive license for valiloxybate with $20 million upfront and potential milestones and royalties.

## Links

- Website: https://www.xwpharma.com/
- LinkedIn: https://www.linkedin.com/company/xwlabs

---

Profile page: https://yespress.io/xwpharma
Published by YesPress — https://yespress.io
Last updated: 2026-09-29